Back to Search
Start Over
Understanding the pharmacokinetics of tulathromycin: a pulmonary perspective
- Source :
- Journal of veterinary pharmacology and therapeutics. 37(3)
- Publication Year :
- 2012
-
Abstract
- Tulathromycin is approved in the United States for the treatment of respiratory disease in bovine and swine, infectious bovine keratoconjunctivitis associated with Moraxella bovis, and interdigital necrobacillosis in bovine. This macrolide highly concentrates in lung tissue and persists in the intra-airway compartment for a long time after a single administration. It also accumulates in inflammatory cells, including neutrophils and macrophages. This article reviews pharmacokinetic information about tulathromycin in different veterinary species with particular emphasis on the respiratory system.
- Subjects :
- Pharmacology
Lung Diseases
General Veterinary
biology
medicine.drug_class
Antibiotics
Respiratory disease
Moraxella bovis
biology.organism_classification
medicine.disease
Disaccharides
Anti-Bacterial Agents
Infectious bovine keratoconjunctivitis
Pharmacokinetics
Heterocyclic Compounds
Immunology
medicine
Animals
Tulathromycin
Respiratory system
Keratoconjunctivitis
Subjects
Details
- ISSN :
- 13652885
- Volume :
- 37
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Journal of veterinary pharmacology and therapeutics
- Accession number :
- edsair.doi.dedup.....8aad8c0de27e41bae48ae1408adb63f9